References

Biederman J, Monuteaux MC, Spencer T, Wilens TE, Macpherson HA, Faraone SV. Stimulant therapy and risk for subsequent substance use disorders in male adults with ADHD: A naturalistic controlled 10-year follow up study. Am J Psychiatry 165(5):597-603, 2008.

Brady KT, Verduin ML. Pharmaco-therapy of comorbid mood, anxiety, and substance use disorders. Subst Use Misuse 40:2021-2041, 2043-2048, 2005.

Caspi A, Moffitt TE, Cannon M, et al. Moderation of the effect of adolescent-onset cannabis use on adult psychosis by a functional polymorphism in the catechol-O-methyltransferase gene: Longitudinal evidence of a gene x environment interaction. Biol Psychiatry 57(10):1117-1127, 2005.

Conway KP, Compton W, Stinson FS, Grant BF. Lifetime comorbidity of DSM-IV mood and anxiety disorders and specific drug use disorders: Results from the National Epidemiologic Survey on Alcohol and Related Conditions. J Clin Psychiatry 67(2):247-257, 2006.

Compton WM, Conway KP, Stinson FS, Colliver JD, Grant BF. Prevalence, correlates, and comorbidity of DSM-IV antisocial personality syndromes and alcohol and specific drug use disorders in the United States: Results from the National Epidemiologic Survey on Alcohol and Related Conditions. J Clin Psychiatry 66(6):677-685, 2005.

James DJ and Glaze E. Mental health problems of prison and jail inmates. Bureau of Justice Statistics Special Report. NCJ 213600, Washington, DC: U.S. Department of Justice, Bureau of Justice Statistics, 2006.

Kessler RC. The epidemiology of dual diagnosis. Biol Psychiatry 56:730-737, 2004.

Lasser K, Boyd JW, Woolhandler S, Himmelstein DU, McCormick D, Bor DH. Smoking and mental illness: A population-based prevalence study. JAMA 284(20):2606-2610, 2000.

Mannuzza S, Klein RG, Truong NL, Moulton JL 3rd, Roizen ER, Howell KH, Castellanos FX. Age of methylphenidate treatment initiation in children with ADHD and later substance abuse: Prospective follow-up into adulthood. Am J Psychiatry 165(5):604-609, 2008.

Negrete JC. Clinical aspects of substance abuse in persons with schizophrenia. Can J Psychiatry 48(1):14-21, 2003.

Nestler EJ, Carlezon WA, Jr. The mesolimbic dopamine reward circuit in depression. Biol Psychiatry 59(12): 1151-1159, 2006.

Quello SB, Brady KT, Sonne SC. Mood disorders and substance abuse disorders: A complex comorbidity. Science & Practice Perspectives 3(1):13-24, 2005.

Riggs PD. Treating adolescents for substance abuse and comorbid psychiatric disorders. Science & Practice Perspectives 2(1):18-28, 2003.

Saal D, Dong Y, Bonci A, Malenka RC. Drugs of abuse and stress trigger a common synaptic adaptation in dopamine neurons. Neuron 37(4): 577-582, 2003.

Uhl GR, Grow RW. The burden of complex genetics in brain disorders. Arch Gen Psychiatry 61(3):223-229, 2004.

Volkow ND. The reality of comorbidity: Depression and drug abuse. Biol Psychiatry 56(10):714-717, 2004.

Volkow ND, Li T-K. Drug addiction: The neurobiology of behavior gone awry. Nat Rev Neurosc 5(12):963-970, 2004.

Weiss RD, Griffin ML, Kolodziej ME, et al. A randomized trial of integrated group therapy versus group drug counseling for patients with bipolar disorder and substance dependence. Am J Psychiatry 164(1):100-107, 2007.

Wilens TE, Faraone SV, Biederman J, Gunawardene S. Does stimulant therapy of attention-deficit/hyperactivity disorder beget later substance abuse? A meta-analytic review of the literature. Pediatrics 111(1):179-185, 2003.